200 related articles for article (PubMed ID: 11896595)
41. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
[TBL] [Abstract][Full Text] [Related]
42. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.
Mitani Y; Oue N; Hamai Y; Aung PP; Matsumura S; Nakayama H; Kamata N; Yasui W
J Pathol; 2005 Jan; 205(1):65-73. PubMed ID: 15586362
[TBL] [Abstract][Full Text] [Related]
43. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription.
Innocente SA; Lee JM
FEBS Lett; 2005 Feb; 579(5):1001-7. PubMed ID: 15710382
[TBL] [Abstract][Full Text] [Related]
44. A functionally inactive p53 Li-Fraumeni syndrome mutant.
Hao M; Finlay CA; Lozano G
Oncogene; 1993 Feb; 8(2):299-306. PubMed ID: 8426739
[TBL] [Abstract][Full Text] [Related]
45. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.
Lin J; Teresky AK; Levine AJ
Oncogene; 1995 Jun; 10(12):2387-90. PubMed ID: 7784087
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
[TBL] [Abstract][Full Text] [Related]
47. AP2alpha alters the transcriptional activity and stability of p53.
Stabach PR; Thiyagarajan MM; Woodfield GW; Weigel RJ
Oncogene; 2006 Apr; 25(15):2148-59. PubMed ID: 16288208
[TBL] [Abstract][Full Text] [Related]
48. p53: an overview of over two decades of study.
Cheah PL; Looi LM
Malays J Pathol; 2001 Jun; 23(1):9-16. PubMed ID: 16329542
[TBL] [Abstract][Full Text] [Related]
49. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
Brazda V; Muller P; Brozkova K; Vojtesek B
Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
[TBL] [Abstract][Full Text] [Related]
50. Structural and functional analysis of p53: the acidic activation domain has transforming capability.
Hulboy DL; Lozano G
Cell Growth Differ; 1994 Oct; 5(10):1023-31. PubMed ID: 7848903
[TBL] [Abstract][Full Text] [Related]
51. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.
Kichina JV; Rauth S; Das Gupta TK; Gudkov AV
Oncogene; 2003 Jul; 22(31):4911-7. PubMed ID: 12894234
[TBL] [Abstract][Full Text] [Related]
52. The UV responsive elements in the human mimecan promoter: a functional characterization.
Tasheva ES; Conrad GW
Mol Vis; 2003 Jan; 9():1-9. PubMed ID: 12533723
[TBL] [Abstract][Full Text] [Related]
53. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P
Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700
[TBL] [Abstract][Full Text] [Related]
54. Temperature-sensitive mutants of p53 associated with human carcinoma of the lung.
Medcalf EA; Takahashi T; Chiba I; Minna J; Milner J
Oncogene; 1992 Jan; 7(1):71-6. PubMed ID: 1741167
[TBL] [Abstract][Full Text] [Related]
55. Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization.
Fen CX; Coomber DW; Lane DP; Ghadessy FJ
J Mol Biol; 2007 Aug; 371(5):1238-48. PubMed ID: 17610896
[TBL] [Abstract][Full Text] [Related]
56. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.
Menendez D; Krysiak O; Inga A; Krysiak B; Resnick MA; Schönfelder G
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1406-11. PubMed ID: 16432214
[TBL] [Abstract][Full Text] [Related]
57. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
[TBL] [Abstract][Full Text] [Related]
58. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
59. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
60. ING1 represses transcription by direct DNA binding and through effects on p53.
Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
